Smithkline Beecham (SBH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH)

SBH 15.11

+4.3%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NucTrader who wrote (44)	1/22/1999 3:52:00 AM
From: Henry Niman	Read Replies (1) of 61

Today's FT has an article on Avandia's priority review. The report indicates that Mehta Partners is predicting that LLY's Actos will be the number #1 seller in its class (TZDs expected to be on market this year include Rezulin, Avandia, and Actos). Details linked to Ligand Diabetes page at biocognizance.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next